Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry-Reference-Cited by-同舟云学术

Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry

Published:2024-01-06 Issue:5 Volume:43 Page:1447-1459
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Harada Hiroshi^ORCID,Kondo Masakazu,Maeyama Akira,Fukuda Takaaki,Ikemura Satoshi,Shono Eisuke,Tsuru Tomomi,Inoue Yasushi,Yoshizawa Seiji,Niiro Hiroaki,Nakashima Yasuharu

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10067-023-06862-8.pdf

Reference21 articles.

1. Genovese MC, Fleischmann R, Kivitz A, Lee EB, van Hoogstraten H, Kimura T, St John G, Mangan EK, Burmester GR (2020) Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Res Ther 22(1):139. https://doi.org/10.1186/s13075-020-02194-z

2. Nakajima A, Inoue E, Shimizu Y, Kobayashi A, Shidara K, Sugimoto N, Seto Y, Tanaka E, Taniguchi A, Momohara S, Yamanaka H (2015) Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. Clin Rheumatol 34(3):441–449. https://doi.org/10.1007/s10067-014-2750-8

3. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TWJ (2013) Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 72(1):43–50. https://doi.org/10.1136/annrheumdis-2011-201282

4. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O, Bernasconi C, Huizinga TWJ (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73(5):803–809. https://doi.org/10.1136/annrheumdis-2013-204761

5. Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A (2018) Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford) 57(3):499–507. https://doi.org/10.1093/rheumatology/kex443

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to: Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry;Clinical Rheumatology;2024-03-15